Ivonescimab Plus Chemotherapy Improves PFS in Advanced EGFR-Mutated NSCLC
Le et alThe Lancet Oncology

In the multicenter, randomized, double-blind, phase 3 HARMONi trial, ivonescimab plus chemotherapy was evaluated against placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) after disease progression on EGFR tyrosine kinase inhibitor (TKI) therapy. The addition of ivonescimab to chemotherapy demonstrated a clinically meaningful and statistically significant progression-free survival benefit without introducing new safety signals, supporting the combination as a potential new therapeutic strategy for this population.
Key Takeaways
- Ivonescimab plus chemotherapy significantly improved progression-free survival compared with placebo plus chemotherapy in advanced EGFR-mutated NSCLC following disease progression on EGFR-TKI therapy.
- No new safety signals were identified with the addition of ivonescimab to chemotherapy, supporting the combination as a potential new treatment option in this patient population.
Read the original sourceThe Lancet Oncology
